| |
著者: Sebastian Wolf, Frank G Holz, Jean-François Korobelnik, Paolo Lanzetta, Paul Mitchell, Christian Prünte, Ursula Schmidt-Erfurth, Andreas Weichselberger, Yehia Hashad
雑誌名: Br J Ophthalmol. 2011 Dec;95(12):1713-8. doi: 10.1136/bjophthalmol-2011-300471. Epub 2011 Sep 27.
Abstract/Text
AIM: This study aims to assess the impact of continued ranibizumab treatment for neovascular age-related macular degeneration on patients from the MARINA and ANCHOR randomised clinical studies who lost ≥ 3 lines of best-corrected visual acuity (BCVA) at any time during the first year of treatment.
METHODS: Baseline characteristics, mean BCVA over time and ocular adverse events (AEs) were evaluated both for patients whose BCVA loss occurred at any post-baseline visit and for patients whose BCVA loss was acute. The visit when the ≥ 3-line BCVA loss was detected was defined as the new baseline.
RESULTS: Continued monthly ranibizumab treatment led to an improvement in mean BCVA from the new baseline. On average, patients with acute BCVA loss gained 11.9 letters at 3 months after the new baseline, compared with 0.3 letters gained with sham. No strong signals were detected in patient demographics and baseline characteristics for prognostic markers of BCVA loss. Furthermore, there was no pattern in the AE profile of patients with acute BCVA loss to suggest that BCVA recovery could be attributed to spontaneously resolving AEs.
CONCLUSION: Continued ranibizumab treatment appears to be beneficial for patients with neovascular age-related macular degeneration who experience a ≥ 3-line BCVA loss during the first year of treatment.
PMID 21951567 Br J Ophthalmol. 2011 Dec;95(12):1713-8. doi: 10.1136/bjophthalmol-2011-300471. Epub 2011 Sep 27.
|
